<DOC>
	<DOCNO>NCT01169558</DOCNO>
	<brief_summary>This expand access study assess safety efficacy intravenous bevacizumab ( 5 mg/kg every 2 week 7.5 mg/kg every 3 week ) combination fluoropyrimidine-based chemotherapy first line treatment participant metastatic cancer colon rectum . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Bevacizumab ( Avastin ) Combination With Chemotherapy Participants With Metastatic Cancer Colon Rectum .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Previously untreated metastatic colon rectal cancer ; Scheduled begin fluoropyrimidinebased chemotherapy first line treatment . Prior chemotherapy metastatic colon rectal cancer ; Planned radiotherapy underlie disease ; central nervous system metastasis ; Major surgical procedure , open biopsy , significant traumatic injury within 28 day study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>